Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?

Current Opinion in Immunology

Volumn 42, Issue , 2016, Pages 48-55

  Neu, Karlynn E ^a   Henry Dunand, Carole J ^a   Wilson, Patrick C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGENIC VARIATION; DISEASE ERADICATION; DRUG DESIGN; DRUG EFFICACY; DRUG SPECIFICITY; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS; MEMORY CELL; NONHUMAN; PROTEIN DOMAIN; REVIEW; SEASONAL INFLUENZA; VIRAL CLEARANCE; VIRUS NEUTRALIZATION; VIRUS STRAIN; B LYMPHOCYTE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLUENZA A VIRUS; METABOLISM; VACCINATION; VIROLOGY;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; B-LYMPHOCYTES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

EID: 84979754039     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.05.012     Document Type: Review

References (89)

1. 1 World Health Organization, Influenza (seasonal) Fact Sheet, vol 2014, 2014, World Health Organization.
2. 2 Palese, MLSaP., Orthomyxoviruses. Knipe, D.M., Howley, P.M., (eds.) Fields Virology, 2013, Lippincott Williams and Wilkins, Philadelphia.
3. 3 de Jong, J.C., Beyer, W.E., Palache, A.M., Rimmelzwaan, G.F., Osterhaus, A.D., Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 61 (2000), 94–99.
4. 4 Medina, R.A., Garcia-Sastre, A., Influenza A viruses: new research developments. Nat Rev Microbiol 9 (2011), 590–603.
5. 5 Hensley, S.E., Das, S.R., Bailey, A.L., Schmidt, L.M., Hickman, H.D., Jayaraman, A., Viswanathan, K., Raman, R., Sasisekharan, R., Bennink, J.R., et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326 (2009), 734–736.
6. 6 Wrammert, J., Smith, K., Miller, J., Langley, W.A., Kokko, K., Larsen, C., Zheng, N.Y., Mays, I., Garman, L., Helms, C., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453 (2008), 667–671.
7. 7 Krystal, M., Elliott, R.M., Benz, E.W. Jr., Young, J.F., Palese, P., Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. Proc Natl Acad Sci U S A 79 (1982), 4800–4804.
8. 8 Ekiert, D.C., Bhabha, G., Elsliger, M.A., Friesen, R.H., Jongeneelen, M., Throsby, M., Goudsmit, J., Wilson, I.A., Antibody recognition of a highly conserved influenza virus epitope. Science 324 (2009), 246–251.
9. 9 Sui, J., Hwang, W.C., Perez, S., Wei, G., Aird, D., Chen, L.M., Santelli, E., Stec, B., Cadwell, G., Ali, M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16 (2009), 265–273.
10. 10 Krammer, F., Palese, P., Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 14 (2015), 167–182.
11. 11 Krammer, F., The quest for a universal flu vaccine: headless HA 2.0. Cell Host Microbe 18 (2015), 395–397.
12. 12 Laver, W.G., Valentine, R.C., Morphology of the isolated hemagglutinin and neuraminidase subunits of influenza virus. Virology 38 (1969), 105–119.
13. 13 Temoltzin-Palacios, F., Thomas, D.B., Modulation of immunodominant sites in influenza hemagglutinin compromise antigenic variation and select receptor-binding variant viruses. J Exp Med 179 (1994), 1719–1724.
14. 14 Wilson, I.A., Skehel, J.J., Wiley, D.C., Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 289 (1981), 366–373.
15. 15 Weis, W., Brown, J.H., Cusack, S., Paulson, J.C., Skehel, J.J., Wiley, D.C., Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 333 (1988), 426–431.
16. 16 Skehel, J.J., Bayley, P.M., Brown, E.B., Martin, S.R., Waterfield, M.D., White, J.M., Wilson, I.A., Wiley, D.C., Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc Natl Acad Sci U S A 79 (1982), 968–972.
17. 17 Bullough, P.A., Hughson, F.M., Skehel, J.J., Wiley, D.C., Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371 (1994), 37–43.
18. 18 Seto, J.T., Rott, R., Functional significance of sialidose during influenza virus multiplication. Virology 30 (1966), 731–737.
19. 19 Marcelin, G., Sandbulte, M.R., Webby, R.J., Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol 22 (2012), 267–279.
20. 20 Nguyen, H.T., Sheu, T.G., Mishin, V.P., Klimov, A.I., Gubareva, L.V., Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother 54 (2010), 3671–3677.
21. 21 Westgeest, K.B., Bestebroer, T.M., Spronken, M.I., Gao, J., Couzens, L., Osterhaus, A.D., Eichelberger, M., Fouchier, R.A., de Graaf, M., Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses. J Virol Methods 217 (2015), 55–63.
22. 22 Air, G.M., Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus. Proc Natl Acad Sci U S A 78 (1981), 7639–7643.
23. 23 Fouchier, R.A., Munster, V., Wallensten, A., Bestebroer, T.M., Herfst, S., Smith, D., Rimmelzwaan, G.F., Olsen, B., Osterhaus, A.D., Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79 (2005), 2814–2822.
24. 24 Zhu, X., Yu, W., McBride, R., Li, Y., Chen, L.M., Donis, R.O., Tong, S., Paulson, J.C., Wilson, I.A., Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities. Proc Natl Acad Sci U S A 110 (2013), 1458–1463.
25. 25 Tong, S., Zhu, X., Li, Y., Shi, M., Zhang, J., Bourgeois, M., Yang, H., Chen, X., Recuenco, S., Gomez, J., et al. New world bats harbor diverse influenza A viruses. PLoS Pathog, 9, 2013, e1003657.
26. 26 Rota, P.A., Wallis, T.R., Harmon, M.W., Rota, J.S., Kendal, A.P., Nerome, K., Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175 (1990), 59–68.
27. 27 Kaur, K., Sullivan, M., Wilson, P.C., Targeting B cell responses in universal influenza vaccine design. Trends Immunol 32 (2011), 524–531.
28. 28 von Itzstein, M., Wu, W.Y., Kok, G.B., Pegg, M.S., Dyason, J.C., Jin, B., Van Phan, T., Smythe, M.L., White, H.F., Oliver, S.W., et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363 (1993), 418–423.
29. 29 Air, G.M., Influenza neuraminidase. Influenza Other Respir Viruses 6 (2012), 245–256.
30. 30 Iba, Y., Fujii, Y., Ohshima, N., Sumida, T., Kubota-Koketsu, R., Ikeda, M., Wakiyama, M., Shirouzu, M., Okada, J., Okuno, Y., et al. Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses. J Virol 88 (2014), 7130–7144.
31. 31 Dreyfus, C., Laursen, N.S., Kwaks, T., Zuijdgeest, D., Khayat, R., Ekiert, D.C., Lee, J.H., Metlagel, Z., Bujny, M.V., Jongeneelen, M., et al. Highly conserved protective epitopes on influenza B viruses. Science 337 (2012), 1343–1348.
32. 32 Schmidt, A.G., Xu, H., Khan, A.R., O'Donnell, T., Khurana, S., King, L.R., Manischewitz, J., Golding, H., Suphaphiphat, P., Carfi, A., et al. Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci U S A 110 (2013), 264–269.
33. 33 Tsibane, T., Ekiert, D.C., Krause, J.C., Martinez, O., Crowe, J.E. Jr., Wilson, I.A., Basler, C.F., Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Pathog, 8, 2012, e1003067.
34. 34 Hong, M., Lee, P.S., Hoffman, R.M., Zhu, X., Krause, J.C., Laursen, N.S., Yoon, S.I., Song, L., Tussey, L., Crowe, J.E. Jr., et al. Antibody recognition of the pandemic H1N1 Influenza virus hemagglutinin receptor binding site. J Virol 87 (2013), 12471–12480.
35. 35 Ekiert, D.C., Kashyap, A.K., Steel, J., Rubrum, A., Bhabha, G., Khayat, R., Lee, J.H., Dillon, M.A., O'Neil, R.E., Faynboym, A.M., et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489 (2012), 526–532.
36. 36 Wrammert, J., Koutsonanos, D., Li, G.M., Edupuganti, S., Sui, J., Morrissey, M., McCausland, M., Skountzou, I., Hornig, M., Lipkin, W.I., et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 208 (2011), 181–193.
37. 37 Lee, P.S., Yoshida, R., Ekiert, D.C., Sakai, N., Suzuki, Y., Takada, A., Wilson, I.A., Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci U S A 109 (2012), 17040–17045.
38. 38 Whittle, J.R., Zhang, R., Khurana, S., King, L.R., Manischewitz, J., Golding, H., Dormitzer, P.R., Haynes, B.F., Walter, E.B., Moody, M.A., et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A 108 (2011), 14216–14221.
39. 39 Yoshida, R., Igarashi, M., Ozaki, H., Kishida, N., Tomabechi, D., Kida, H., Ito, K., Takada, A., Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. PLoS Pathog, 5, 2009, e1000350.
40. 40 Krause, J.C., Tsibane, T., Tumpey, T.M., Huffman, C.J., Basler, C.F., Crowe, J.E. Jr., A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. J Virol 85 (2011), 10905–10908.
41. 41 Xu, R., Krause, J.C., McBride, R., Paulson, J.C., Crowe, J.E. Jr., Wilson, I.A., A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat Struct Mol Biol 20 (2013), 363–370.
42. 42•• Schmidt, A.G., Therkelsen, M.D., Stewart, S., Kepler, T.B., Liao, H.X., Moody, M.A., Haynes, B.F., Harrison, S.C., Viral receptor-binding site antibodies with diverse germline origins. Cell 161 (2015), 1026–1034 Schmidt et al., identify the signature motif for the receptor-binding site-specific antibodies.
43. 43 Ekiert, D.C., Friesen, R.H., Bhabha, G., Kwaks, T., Jongeneelen, M., Yu, W., Ophorst, C., Cox, F., Korse, H.J., Brandenburg, B., et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333 (2011), 843–850.
44. 44 Corti, D., Voss, J., Gamblin, S.J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S.G., Pinna, D., Minola, A., Vanzetta, F., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333 (2011), 850–856.
45. 45• Henry Dunand, C.J., Leon, P.E., Kaur, K., Tan, G.S., Zheng, N.Y., Andrews, S., Huang, M., Qu, X., Huang, Y., Salgado-Ferrer, M., et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest 125 (2015), 1255–1268 The authors show that preexisting cross-reactive immunity offers protection against novel emerging influenza strains.
46. 46 Friesen, R.H., Lee, P.S., Stoop, E.J., Hoffman, R.M., Ekiert, D.C., Bhabha, G., Yu, W., Juraszek, J., Koudstaal, W., Jongeneelen, M., et al. A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A 111 (2014), 445–450.
47. 47 Throsby, M., van den Brink, E., Jongeneelen, M., Poon, L.L., Alard, P., Cornelissen, L., Bakker, A., Cox, F., van Deventer, E., Guan, Y., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One, 3, 2008, e3942.
48. 48 Li, G.M., Chiu, C., Wrammert, J., McCausland, M., Andrews, S.F., Zheng, N.Y., Lee, J.H., Huang, M., Qu, X., Edupuganti, S., et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A 109 (2012), 9047–9052.
49. 49 Wang, T.T., Tan, G.S., Hai, R., Pica, N., Petersen, E., Moran, T.M., Palese, P., Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog, 6, 2010, e1000796.
50. 50 Yasugi, M., Kubota-Koketsu, R., Yamashita, A., Kawashita, N., Du, A., Sasaki, T., Nishimura, M., Misaki, R., Kuhara, M., Boonsathorn, N., et al. Human monoclonal antibodies broadly neutralizing against influenza B virus. PLoS Pathog, 9, 2013, e1003150.
51. 51•• Henry Dunand, C.J., Leon, P.E., Huang, M., Choi, A., Chromikova, V., Ho, I.Y., Tan, G.S., Cruz, J., Hirsh, A., Zheng, N.Y., et al. Neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies offer protection in vivo. Cell Host Microbe, 2016 PMID: 27081859, in press This paper identifies protective non-neutralizing antibodies from vaccinated individuals. These antibodies target conserved epitopes on the HA protein and rely on Fc-FcγR interactions to mediate protection.
52. 52• Tan, G.S., Leon, P.E., Albrecht, R.A., Margine, I., Hirsh, A., Bahl, J., Krammer, F., Broadly-reactive neutralizing and non-neutralizing antibodies directed against 2 the H7 influenza virus hemagglutinin reveal divergent mechanisms of protection. PLoS Pathog, 2016 In press Tan et al., identify protective non-neutralizing antibodies in mice following H7 HA immunization that bind at the interface between the head and the stalk domain.
53. 53 Jegaskanda, S., Job, E.R., Kramski, M., Laurie, K., Isitman, G., de Rose, R., Winnall, W.R., Stratov, I., Brooks, A.G., Reading, P.C., et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 190 (2013), 1837–1848.
54. 54 Terajima, M., Co, M.D., Cruz, J., Ennis, F.A., High antibody-dependent cellular cytotoxicity antibody titers to H5N1 and H7N9 avian influenza A viruses in healthy US adults and older children. J Infect Dis 212 (2015), 1052–1060.
55. 55 Krammer, F., Jul-Larsen, A., Margine, I., Hirsh, A., Sjursen, H., Zambon, M., Cox, R.J., An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin Vaccine Immunol 21 (2014), 1153–1163.
56. 56 Moody, M.A., Zhang, R., Walter, E.B., Woods, C.W., Ginsburg, G.S., McClain, M.T., Denny, T.N., Chen, X., Munshaw, S., Marshall, D.J., et al. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One, 6, 2011, e25797.
57. 57 Margine, I., Hai, R., Albrecht, R.A., Obermoser, G., Harrod, A.C., Banchereau, J., Palucka, K., Garcia-Sastre, A., Palese, P., Treanor, J.J., et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol 87 (2013), 4728–4737.
58. 58 Corti, D., Suguitan, A.L. Jr., Pinna, D., Silacci, C., Fernandez-Rodriguez, B.M., Vanzetta, F., Santos, C., Luke, C.J., Torres-Velez, F.J., Temperton, N.J., et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120 (2010), 1663–1673.
59. 59 Miller, M.S., Tsibane, T., Krammer, F., Hai, R., Rahmat, S., Basler, C.F., Palese, P., 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis 207 (2013), 98–105.
60. 60 Sui, J., Sheehan, J., Hwang, W.C., Bankston, L.A., Burchett, S.K., Huang, C.Y., Liddington, R.C., Beigel, J.H., Marasco, W.A., Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis 52 (2011), 1003–1009.
61. 61 Sangster, M.Y., Baer, J., Santiago, F.W., Fitzgerald, T., Ilyushina, N.A., Sundararajan, A., Henn, A.D., Krammer, F., Yang, H., Luke, C.J., et al. B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin Vaccine Immunol 20 (2013), 867–876.
62. 62 Thomson, C.A., Wang, Y., Jackson, L.M., Olson, M., Wang, W., Liavonchanka, A., Keleta, L., Silva, V., Diederich, S., Jones, R.B., et al. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front Immunol, 3, 2012, 87.
63. 63 Ellebedy, A.H., Krammer, F., Li, G.M., Miller, M.S., Chiu, C., Wrammert, J., Chang, C.Y., Davis, C.W., McCausland, M., Elbein, R., et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A 111 (2014), 13133–13138.
64. 64 Guan, Y., Vijaykrishna, D., Bahl, J., Zhu, H., Wang, J., Smith, G.J., The emergence of pandemic influenza viruses. Protein Cell 1 (2010), 9–13.
65. 65 Kilbourne, E.D., Cerini, C.P., Khan, M.W., Mitchell, J.W. Jr., Ogra, P.L., Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccines. J Immunol 138 (1987), 3010–3013.
66. 66 Palese, P., Wang, T.T., Why do influenza virus subtypes die out?. A hypothesis. MBio, 2011, 2.
67. 67 Pica, N., Hai, R., Krammer, F., Wang, T.T., Maamary, J., Eggink, D., Tan, G.S., Krause, J.C., Moran, T., Stein, C.R., et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A 109 (2012), 2573–2578.
68. 68• Reperant, L.A., Kuiken, T., Osterhaus, A.D., Adaptive pathways of zoonotic influenza viruses: from exposure to establishment in humans. Vaccine 30 (2012), 4419–4434 Ellebedy et al., report that antibodies and memory B cells directed against the HA stalk domain are prevalent in humans and that H5N1 vaccination induces broadly-reactive stalk antibodies.
69. 69•• Andrews, S.F., Huang, Y., Kaur, K., Popova, L.I., Ho, I.Y., Pauli, N.T., Henry Dunand, C.J., Taylor, W.M., Lim, S., Huang, M., et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med, 7, 2015, 316ra192 The study shows that preexisting head antibodies are immunodominant, preventing clear access to the stalk and that stalk-reactive antibodies are couterselected due to polyreactivity.
70. 70 Halliley, J.L., Khurana, S., Krammer, F., Fitzgerald, T., Coyle, E.M., Chung, K.Y., Baker, S.F., Yang, H., Martinez-Sobrido, L., Treanor, J.J., et al. High-affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine. J Infect Dis 212 (2015), 1270–1278.
71. 71 Nachbagauer, R., Choi, A., Izikson, R., Cox, M.M., Palese, P., Krammer, F., Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans. MBio, 2016, 7.
72. 72 Li, Y., Myers, J.L., Bostick, D.L., Sullivan, C.B., Madara, J., Linderman, S.L., Liu, Q., Carter, D.M., Wrammert, J., Esposito, S., et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med 210 (2013), 1493–1500.
73. 73 Miller, M.S., Gardner, T.J., Krammer, F., Aguado, L.C., Tortorella, D., Basler, C.F., Palese, P., Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med, 5, 2013, 198ra107.
74. 74 Graves, P.N., Schulman, J.L., Young, J.F., Palese, P., Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 126 (1983), 106–116.
75. 75 Steel, J., Lowen, A.C., Wang, T.T., Yondola, M., Gao, Q., Haye, K., Garcia-Sastre, A., Palese, P., Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio, 2010, 1.
76. 76 Harris, A.K., Meyerson, J.R., Matsuoka, Y., Kuybeda, O., Moran, A., Bliss, D., Das, S.R., Yewdell, J.W., Sapiro, G., Subbarao, K., et al. Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci U S A 110 (2013), 4592–4597.
77. 77 Henry Dunand, C.J., Wilson, P.C., Restricted, canonical, stereotyped and convergent immunoglobulin responses. Philos Trans R Soc Lond B Biol Sci, 2015, 370.
78. 78•• Avnir, Y., Tallarico, A.S., Zhu, Q., Bennett, A.S., Connelly, G., Sheehan, J., Sui, J., Fahmy, A., Huang, C.Y., Cadwell, G., et al. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog, 10, 2014, e1004103 The authors identify the key residues used by VH1–69 stalk-reactive antibodies.
79. 79 Whittle, J.R., Wheatley, A.K., Wu, L., Lingwood, D., Kanekiyo, M., Ma, S.S., Narpala, S.R., Yassine, H.M., Frank, G.M., Yewdell, J.W., et al. Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol 88 (2014), 4047–4057.
80. 80 Mouquet, H., Scheid, J.F., Zoller, M.J., Krogsgaard, M., Ott, R.G., Shukair, S., Artyomov, M.N., Pietzsch, J., Connors, M., Pereyra, F., et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467 (2010), 591–595.
81. 81 Mouquet, H., Warncke, M., Scheid, J.F., Seaman, M.S., Nussenzweig, M.C., Enhanced HIV-1 neutralization by antibody heteroligation. Proc Natl Acad Sci U S A 109 (2012), 875–880.
82. 82 Wardemann, H., Yurasov, S., Schaefer, A., Young, J.W., Meffre, E., Nussenzweig, M.C., Predominant autoantibody production by early human B cell precursors. Science 301 (2003), 1374–1377.
83. 83 Krammer, F., Palese, P., Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3 (2013), 521–530.
84. 84 Krammer, F., Pica, N., Hai, R., Margine, I., Palese, P., Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87 (2013), 6542–6550.
85. 85 Margine, I., Krammer, F., Hai, R., Heaton, N.S., Tan, G.S., Andrews, S.A., Runstadler, J.A., Wilson, P.C., Albrecht, R.A., Garcia-Sastre, A., et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 87 (2013), 10435–10446.
86. 86 Babu, T.M., Levine, M., Fitzgerald, T., Luke, C., Sangster, M.Y., Jin, H., Topham, D., Katz, J., Treanor, J., Subbarao, K., Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine 32 (2014), 6798–6804.
87. 87 Goff, P.H., Eggink, D., Seibert, C.W., Hai, R., Martinez-Gil, L., Krammer, F., Palese, P., Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One, 8, 2013, e79194.
88. 88 Krammer, F., Novel universal influenza virus vaccine approaches. Curr Opin Virol 17 (2016), 95–103.
89. 89•• Tran, E.E., Podolsky, K.A., Bartesaghi, A., Kuybeda, O., Grandinetti, G., Wohlbold, T.J., Tan, G.S., Nachbagauer, R., Palese, P., Krammer, F., et al. Cryo-electron microscopy structures of chimeric hemagglutinin displayed on a universal influenza vaccine candidate. MBio, 2016, 7 This paper reports the first three-dimensional (3D) visualization of chimeric hemagglutinin proteins displayed on the surface of the influenza virus, in the context of a candidate universal influenza vaccine.